Head and neck cancer patient-derived xenograft models - A systematic review

Autor(es)

Schuch, Lauren F. ^[1] ; Silveira, Felipe M. ^[1] ; Wagner, Vivian P. ^[1] ; Borgato, Gabriell B. ^[1] ; Rocha, Guilherme Z. ^[1] ; Castilho, Rogerio M. ^{[2, 3]} ; Vargas, Pablo A. ^[1] ; Martins, Manoela D. ^{[1, 4]}

Afiliação do(s) autor(es)

^[1] Univ Estadual Campinas, Piracicaba Dent Sch, Dept Oral Diag, Piracicaba, SP - Brazil

^[2] Univ Michigan, Sch Dent, Lab Epithelial Biol, Dept Periodont & Oral Med, Ann Arbor, MI 48109 - USA

^[3] Univ Michigan, Comprehens Canc Ctr, Ann Arbor, MI 48109 - USA

^[4] Univ Fed Rio Grande do Sul, Sch Dent, Dept Oral Pathol, Porto Alegre, RS - Brazil

• Tipo de documento: Artigo de Revisão
• Fonte: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY; v. 155, NOV 2020.
• Citações Web of Science: 0

Resumo

Background: Patient-derived xenograft (PDX) involve the direct surgical transfer of fresh human tumor samples to immunodeficient mice. This systematic review aimed to identify publications of head and neck cancer PDX (HNC-PDX) models, describing the main methodological characteristics and outcomes. Methods: An electronic search was undertaken in four databases, including publications having used HNC-PDX. Data were analyzed descriptively. Results: 63 articles were yielded. The nude mouse was one most commonly animal model used (38.8 %), and squamous cell carcinoma accounted for the majority of HNC-PDX (80.6 %). Tumors were mostly implanted in the flank (86.3 %), and the latency period ranged from 30 to 401 days. The successful rate ranged from 17 % to 100 %. Different drugs and pathways were identified. Conclusion: HNC-PDX appears to significantly recapitulate the morphology of the original HNC and represents a valuable method in translational research for the assessment of the in vivo effect of novel therapies for HNC. (AU)

• Processo FAPESP: 16/21785-4 - Relação da via de sinalização BDNF/TRKB com a agressividade e perfil de células tronco tumorais de neoplasias malignas de glândula salivar
• Beneficiário: Vivian Petersen Wagner
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado